Clinical trial

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-01-07

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2020-01-07Date precision: day

Registry last updated2026-09-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCunresolved

Interventions

REGN5093DRUG

Sponsors & collaborators

Regeneron Pharmaceuticalslead sponsor

Mapped research locations

SeoulSouth Korea7 New YorkNew York, United States2 HoustonTexas, United States1 BostonMassachusetts, United States1 PittsburghPennsylvania, United States1 TampaFlorida, United States1 Washington D.C.District of Columbia, United States1 MontpellierFrance1 OrangeCalifornia, United States1 GrenobleFrance1 BusanSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04077099 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.